HALOZYME THERAPEUTICS INC (HALO) Stock Fundamental Analysis
USA - NASDAQ:HALO - US40637H1095 - Common Stock
65.19 USD
+0.56 (+0.87%)
65.19 USD
0 (0%)
We assign a fundamental rating of 8 out of 10 to HALO. HALO was compared to 534 industry peers in the Biotechnology industry. HALO has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. HALO is growing strongly while it also seems undervalued. This is an interesting combination With these ratings, HALO could be worth investigating further for value and growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year HALO was profitable.
HALO had a positive operating cash flow in the past year.
HALO had positive earnings in each of the past 5 years.
In the past 5 years HALO always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 27.13%, HALO belongs to the best of the industry, outperforming 97.75% of the companies in the same industry.
With an excellent Return On Equity value of 167.48%, HALO belongs to the best of the industry, outperforming 99.63% of the companies in the same industry.
HALO has a Return On Invested Capital of 28.55%. This is amongst the best in the industry. HALO outperforms 98.88% of its industry peers.
The Average Return On Invested Capital over the past 3 years for HALO is above the industry average of 15.51%.
The last Return On Invested Capital (28.55%) for HALO is above the 3 year average (17.81%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 27.13% | ||
| ROE | 167.48% | ||
| ROIC | 28.55% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
1.3 Margins
Looking at the Profit Margin, with a value of 47.28%, HALO belongs to the top of the industry, outperforming 98.88% of the companies in the same industry.
HALO's Profit Margin has declined in the last couple of years.
The Operating Margin of HALO (57.92%) is better than 99.81% of its industry peers.
HALO's Operating Margin has declined in the last couple of years.
The Gross Margin of HALO (84.20%) is better than 87.08% of its industry peers.
In the last couple of years the Gross Margin of HALO has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 57.92% | ||
| PM (TTM) | 47.28% | ||
| GM | 84.2% |
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HALO is creating value.
Compared to 1 year ago, HALO has less shares outstanding
HALO has less shares outstanding than it did 5 years ago.
HALO has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.15 indicates that HALO is not in any danger for bankruptcy at the moment.
HALO has a better Altman-Z score (5.15) than 74.53% of its industry peers.
The Debt to FCF ratio of HALO is 2.79, which is a good value as it means it would take HALO, 2.79 years of fcf income to pay off all of its debts.
HALO's Debt to FCF ratio of 2.79 is amongst the best of the industry. HALO outperforms 93.82% of its industry peers.
HALO has a Debt/Equity ratio of 4.54. This is a high value indicating a heavy dependency on external financing.
HALO has a worse Debt to Equity ratio (4.54) than 81.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.54 | ||
| Debt/FCF | 2.79 | ||
| Altman-Z | 5.15 |
ROIC/WACC3.64
WACC7.84%
2.3 Liquidity
A Current Ratio of 8.36 indicates that HALO has no problem at all paying its short term obligations.
HALO's Current ratio of 8.36 is fine compared to the rest of the industry. HALO outperforms 74.72% of its industry peers.
A Quick Ratio of 7.01 indicates that HALO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.01, HALO is in the better half of the industry, outperforming 69.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.01 |
3. Growth
3.1 Past
HALO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.41%, which is quite impressive.
The Earnings Per Share has been growing by 30.12% on average over the past years. This is a very strong growth
Looking at the last year, HALO shows a very strong growth in Revenue. The Revenue has grown by 34.97%.
HALO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.95% yearly.
EPS 1Y (TTM)58.41%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%69.23%
Revenue 1Y (TTM)34.97%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%40.79%
3.2 Future
Based on estimates for the next years, HALO will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.27% on average per year.
HALO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.85% yearly.
EPS Next Y48.46%
EPS Next 2Y38.68%
EPS Next 3Y32.65%
EPS Next 5Y18.27%
Revenue Next Year31.48%
Revenue Next 2Y27.69%
Revenue Next 3Y23.78%
Revenue Next 5Y13.85%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 12.58, HALO is valued correctly.
Compared to the rest of the industry, the Price/Earnings ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 97.38% of the companies listed in the same industry.
HALO's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.11.
A Price/Forward Earnings ratio of 8.01 indicates a reasonable valuation of HALO.
98.50% of the companies in the same industry are more expensive than HALO, based on the Price/Forward Earnings ratio.
HALO's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.55.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.58 | ||
| Fwd PE | 8.01 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HALO is valued cheaper than 96.25% of the companies in the same industry.
96.82% of the companies in the same industry are more expensive than HALO, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.1 | ||
| EV/EBITDA | 10.6 |
4.3 Compensation for Growth
HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of HALO may justify a higher PE ratio.
A more expensive valuation may be justified as HALO's earnings are expected to grow with 32.65% in the coming years.
PEG (NY)0.26
PEG (5Y)N/A
EPS Next 2Y38.68%
EPS Next 3Y32.65%
5. Dividend
5.1 Amount
No dividends for HALO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
65.19
+0.56 (+0.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners102.63%
Inst Owner Change-1.94%
Ins Owners0.85%
Ins Owner Change-0.2%
Market Cap7.63B
Revenue(TTM)1.18B
Net Income(TTM)557.28M
Analysts75
Price Target77.18 (18.39%)
Short Float %9.96%
Short Ratio5.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.03%
Min EPS beat(2)14.79%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)16.87%
Min EPS beat(4)6.64%
Max EPS beat(4)26.79%
EPS beat(8)7
Avg EPS beat(8)12.25%
EPS beat(12)10
Avg EPS beat(12)12.69%
EPS beat(16)13
Avg EPS beat(16)10.59%
Revenue beat(2)2
Avg Revenue beat(2)12.25%
Min Revenue beat(2)11.69%
Max Revenue beat(2)12.81%
Revenue beat(4)4
Avg Revenue beat(4)9.78%
Min Revenue beat(4)1.36%
Max Revenue beat(4)13.28%
Revenue beat(8)5
Avg Revenue beat(8)5.19%
Revenue beat(12)7
Avg Revenue beat(12)3.36%
Revenue beat(16)9
Avg Revenue beat(16)2.8%
PT rev (1m)5.83%
PT rev (3m)13.57%
EPS NQ rev (1m)-0.2%
EPS NQ rev (3m)10.17%
EPS NY rev (1m)-0.14%
EPS NY rev (3m)11.94%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)2.73%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)5.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.58 | ||
| Fwd PE | 8.01 | ||
| P/S | 6.47 | ||
| P/FCF | 14.1 | ||
| P/OCF | 13.92 | ||
| P/B | 22.92 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.6 |
EPS(TTM)5.18
EY7.95%
EPS(NY)8.14
Fwd EY12.48%
FCF(TTM)4.62
FCFY7.09%
OCF(TTM)4.68
OCFY7.18%
SpS10.08
BVpS2.84
TBVpS-3.85
PEG (NY)0.26
PEG (5Y)N/A
Graham Number18.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 27.13% | ||
| ROE | 167.48% | ||
| ROCE | 35.56% | ||
| ROIC | 28.55% | ||
| ROICexc | 39.96% | ||
| ROICexgc | 93.15% | ||
| OM | 57.92% | ||
| PM (TTM) | 47.28% | ||
| GM | 84.2% | ||
| FCFM | 45.87% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexgc growth 3Y-1.13%
ROICexgc growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.54 | ||
| Debt/FCF | 2.79 | ||
| Debt/EBITDA | 1.97 | ||
| Cap/Depr | 8.67% | ||
| Cap/Sales | 0.6% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 71.66% | ||
| Profit Quality | 97.02% | ||
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.01 | ||
| Altman-Z | 5.15 |
F-Score8
WACC7.84%
ROIC/WACC3.64
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)58.41%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%69.23%
EPS Next Y48.46%
EPS Next 2Y38.68%
EPS Next 3Y32.65%
EPS Next 5Y18.27%
Revenue 1Y (TTM)34.97%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%40.79%
Revenue Next Year31.48%
Revenue Next 2Y27.69%
Revenue Next 3Y23.78%
Revenue Next 5Y13.85%
EBIT growth 1Y68.72%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.62%
EBIT Next 3Y39.07%
EBIT Next 5Y15.57%
FCF growth 1Y84.66%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y79.07%
OCF growth 3Y16.96%
OCF growth 5YN/A
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 8 / 10 to HALO.
What is the valuation status for HALO stock?
ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.
Can you provide the profitability details for HALOZYME THERAPEUTICS INC?
HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.
What is the valuation of HALOZYME THERAPEUTICS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for HALOZYME THERAPEUTICS INC (HALO) is 12.58 and the Price/Book (PB) ratio is 22.92.
How financially healthy is HALOZYME THERAPEUTICS INC?
The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 8 / 10.